Related Experiment Video
Updated: Aug 25, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
How many mutant p53 molecules are needed to inactivate a tetramer?
Wan Mui Chan1, Wai Yi Siu, Anita Lau
1Department of Biochemistry, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong.
Abstract:
The tumor suppressor p53 is transcription factor composed of four identical subunits. The majority of the mutations in p53 are missense mutations that impair DNA binding. On the other hand, the p53-related p63 and p73 genes are rarely mutated, but many cell types express natural variants lacking the N-terminal transactivation domain (NDelta). Compelling evidence indicates that both the DNA binding-defective and NDelta mutants can impair the function of wild-type p53 in a dominant-negative manner. Interestingly, it is uncertain how many mutant subunit(s) a p53 tetramer can tolerate. In this study, we first made theoretical predictions based on the number of mutant p53 monomers needed to inactivate a tetramer and then tested how well the experimental data fit the predicted values. Surprisingly, these experiments reveal that DNA binding-defective p53 mutants (R249S and R273H) are very ineffective in impairing the transcriptional activity of p53: at least three mutants are required to inactivate a tetramer. In marked contrast, p53NDelta is a very potent inhibitor of p53: one NDelta subunit per tetramer is sufficient to abolish the transcriptional activity. DNA binding is not necessary for the NDelta proteins to inactivate p53. Similarly, NDelta variants of p63 and p73 are also powerful inhibitors of members of the p53 family. These results have important implications for our thinking about the mechanism of tumorigenesis involving missense p53 mutants or the N-terminally truncated isoforms.
Insights
The tumor suppressor p53 protein
Area of Science:
- Molecular Biology
- Cancer Genetics
Background:
- The tumor suppressor p53 protein is a transcription factor crucial for preventing cancer.
- Most p53 mutations are missense mutations affecting DNA binding.
- p53-related proteins p63 and p73 have variants lacking the N-terminal transactivation domain (NDelta).
Purpose of the Study:
- To investigate the dominant-negative effects of p53 mutants on wild-type p53 function.
- To determine the number of mutant subunits required to inactivate a p53 tetramer.
- To compare the inhibitory potential of DNA-binding defective mutants versus N-terminally truncated variants.
Main Methods:
- Theoretical predictions of mutant p53 monomer requirements for tetramer inactivation.
- Experimental validation of theoretical predictions using specific p53 mutants (R249S, R273H).
- Assessment of p53NDelta and related NDelta variants' inhibitory capacity.
Main Results:
- DNA-binding defective p53 mutants (R249S, R273H) are poor inhibitors, requiring at least three mutants to inactivate a tetramer.
- p53NDelta is a potent inhibitor, with one NDelta subunit per tetramer abolishing transcriptional activity.
- NDelta variants of p63 and p73 also potently inhibit p53 family members, independent of DNA binding.
Conclusions:
- The mechanism of dominant-negative inhibition by p53 mutants varies significantly.
- N-terminally truncated p53 variants (p53NDelta) are much more potent inhibitors than DNA-binding defective mutants.
- These findings impact understanding of tumorigenesis involving p53 mutations and truncated isoforms.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...

